anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
During the 16-week intervention, subjects will be randomly assigned to 1 of 3 groups including consuming normal-protein diet, higher-protein diet supplemented with micellar casein protein or higher-protein diet supplemented with soy protein. Recommended Dietary Allowances for healthy Singaporean. Normal-protein diet will be designed following a healthy eating pattern diet, referred to as the "My Healthy Plate" launched by Health Promotion Board and subjects will consume 3 servings of dietary protein. Higher-protein diet will also follow a healthy eating pattern diet while subjects will additionally take either 20 g micellar casein protein isolate or 20 g soy protein isolate. One-on-one dietary counselling and written instructions for each subject will be provided by a research dietitian and trained research staff. Compliance with the diet interventions will be promoted by frequent online and in-person contact and dietary assessment. Blood amino acid concentration will also be assessed as an indicator of compliance to the protein intake.
Therapeutic chimeric ligand binding proteins are disclosed that are made from portions of at least two receptors that are fused into a single polypeptide sequence. The fused receptor portions can be derived from ErbB, an Axl receptor, FGFR, PDGFR, an Eph receptor, a Tie receptor, c-Kit receptor, a Trk receptor, a FLT3 receptor, the c-Met oncogene, or their family members and their isoforms. The resulting fusion protein has detectable binding activity for ligands that bind to each of its receptor substituents. DNA sequences that encode the chimeric ligand binding proteins are also contemplated along with sequences that facilitate expression and host cells for the maintenance and expression of such DNA sequences. Pharmaceutical compositions that contain the chimeric ligand binding proteins and a pharmaceutically acceptable excipient are also contemplated. Methods for treating patients having diseases that are associated with ligand binding are also contemplated that involve administering a pharmaceutical composition that contain therapeutically effective amounts of one or more of the chimeric ligand binding protein in a pharmaceutically acceptable excipient or using the chimeric ligand binding proteins to filter bodily fluids.
C1-inactivator can be used to combat complications during operations using conditions involving extracorporeal circulation. USE - C1-inactivator has a positive effect in the therapy of progressive dysfunction of organ systems and reduced heart performance (in patients with extracorporeal circulation). The C1-inactivator combats the symptoms such as generalised oedema and refractory hypotension produced by activation of the hallikrein system in cases where not enough C1-inactivator is produced naturally to control the kallikrein system. Suitable daily doses are 1-5000 (esp. 5-1000) units/kg administered intravenously (bolus or infusion) intra-muscularly or subcutaneously. Solid pharmaceutical forms contain 1-300,000 (esp. 50-60000) units daily for use p.o. or rectally.
The present invention relates to the identification and characterization of a receptor associated with antigen presentation in immune responses, endocytosis, and transepithelial transport. Identification of the receptor, its characterization as having ten lectin-binding domains, and evidence of its role in the uptake and processing of oligosaccharides and oligosaccharide-decorated molecules, e.g. glycoproteins, has important ramifications for modifying immune response, and for trans-epithelial transport of molecules. The receptor, or integral membrane protein, termed herein "DEC", is found primarily on dendritic cells, but also found on B cells, brain capillaries, bone marrow stroma, epithelia of intestinal villi and pulmonary airways, as well as cortical epithelium of the thymus and the dendritic cells in the T cell areas of peripheral lymphoid organs. The murine and human counterparts of DEC have an apparent molecular mass of 205 kDa, the murine counterpart has an isoelectric point at pH 7.5, and carbohydrates comprise about 7 kDa of the total mass of murine DEC. The present invention is directed to identification of additional ligands of DEC, which can be advantageously targeted to dendritic cells and other cells that bear DEC. Targeting antigens for presentation by dendritic cells can provide for tolerance when the dendritic cells are quiescent, or for immune stimulation (i.e., vaccination) when the dendritic cells are activated, e.g., by stimulation with a cytokine or lymphokine, such as colony stimulating factor (CSF).
PURPOSE: The present study aimed to investigate CT imaging features, pathological findings, and prognosis in patients with thyroid hemiatrophy (THA) associated with papillary thyroid carcinoma (PTC).
METHODS: This retrospective study included 225 patients with histopathologically proven PTC treated by surgical resection who underwent preoperative CT scanning. On CT images, THA was defined as thyroid parenchymal hemiatrophy on the ipsilateral side of PTC. CT findings, overall survival, and disease-free survival were compared between patients with and without THA. Pathological findings were also assessed in PTCs with and without THA.
RESULTS: THA was observed in 35 of 225 (16%) patients with PTC. Atrophic thyroid parenchyma was observed in the right lobe of 20 patients (57%) and in the left lobe of the remaining 15 patients (43%). With respect to the solid components within PTCs, contrast-enhanced CT attenuation (114.2 ± 18.2 vs. 126.7 ± 31.3 HU; p < 0.05) and CT attenuation change for contrast-enhanced CT minus unenhanced CT (60.2 ± 18.1 vs. 72.3 ± 31.0 HU; p < 0.05) were significantly lower in PTCs with THA than in those without THA. Histopathologically, almost all PTCs with THA (97%) had keloid-like collagen, which is broad bundles of hypocellular collagen with bright eosinophilic hyalinization, typically observed in keloid. However, no significant differences were observed in the prognosis between the two groups.
CONCLUSION: THA was occasionally observed in patients with PTC. Weak contrast-enhancement was distinct characteristic of PTC patients with THA, which is probably caused by keloid-like collagen.
Subjects will receive DTG 50 mg QD on Days 1 through 5 in Period 1 followed by a wash-out period of 4 days. Subjects will then receive GSK3640254 200 mg QD on Days 1 through 7 in Period 2 followed by co-administration of DTG 50 mg QD with GSK3640254 200 mg QD on Days 1 through 7 in Period 3.
Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx) and daily TMZ at 75 mg/m2 qd concurrent with IMRT (including weekends and holidays). Bevacizumab will be administered at 10 mg/kg on day 1 and day 15. Day 1 and the 1st Fx of IMRT must start on the same day. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab therapy, patients will have a brain MRI and if there is no evidence of disease progression, patients will receive 6 cycles of Bevacizumab and TMZ. Beginning a minimum of 28 days after the last radiation treatment the bevacizumab will be dosed at 10 mg/kg on day 1 and day 15 of each cycle. TMZ will be given at 150-200 mg/m2 qd on days 1-5 of each cycle. Each cycle is 28 days.
Breast cancer, a complex disease with a significant prevalence to form metastases, necessitates novel therapeutic strategies to improve treatment outcomes. Here, we present the results of a comparative molecular study of primary breast tumours, their metastases, and the corresponding primary cell lines using Desorption Electrospray Ionisation (DESI) and Laser-Assisted Rapid Evaporative Ionisation Mass Spectrometry (LA-REIMS) imaging. Our results show that ambient ionisation mass spectrometry technology is suitable for rapid characterisation of samples, providing a lipid- and metabolite-rich spectrum within seconds. Our study demonstrates that the lipidomic fingerprint of the primary tumour is not significantly distinguishable from that of its metastasis, in parallel with the similarity observed between their respective primary cell lines. While significant differences were observed between tumours and the corresponding cell lines, distinct lipidomic signatures and several phospholipids such as PA(36:2), PE(36:1), and PE(P-38:4)/PE(O-38:5) for LA-REIMS imaging and PE(P-38:4)/PE(O-38:5), PS(36:1), and PI(38:4) for DESI-MSI were identified in both tumours and cells. We show that the tumours' characteristics can be found in the corresponding primary cell lines, offering a promising avenue for assessing tumour responsiveness to therapeutic interventions. A comparative analysis by DESI-MSI and LA-REIMS imaging revealed complementary information, demonstrating the utility of LA-REIMS in the molecular imaging of cancer.
PURPOSE:To obtain the titled liniment, by dipping Houttuynia cordata in water to remove harshness, fermenting the Houttuynia cordata, mixing the resultant pressed juice as a parent material with a vegetable raw material, e.g. Cnidii Rhizoma, etc., fermenting the mixture and digesting the mixture until a colloidal material is formed. CONSTITUTION:Houttuynia cordata is dipped in water for about 1 week to remove harshness and carry out fermentation at the same time. The resultant material is squeezed. 14g total of 16 kinds of vegetable raw materials shown in table I is mixed with the resultant juice and ordinary cold water is added. The mixture is then hermetically sealed in a brown vessel at ordinary temperature without kneading or shaking and fermented by storing in a cold and dark place for about 3 months. When the mixture becomes a colloidal composite juice having overall dry various effects, the aimed vegetable liniment is obtained. If this agent is rubbed in both sides of required joints of the vertebra according to the state and condition of pain, the agent rapidly permeates to mix with blood and exhibits the remedial effect in the affected part. The agent is both medically and surgically effective.
PROBLEM TO BE SOLVED: To obtain an arrangement chemicals sale managing device by which computer conversion is easily executed and the data is processed by permitting portable information equipment to issue an adjustment slip where a client name, the names of arranged chemicals, a usage number and an usage money amount or the like are printed and to issue a receipt corresponding to money reception when money is received. SOLUTION: An I/O port 22 is connected to CPU 20 of portable information equipment 10. A liquid crystal display device 14, RAM, ROM and a memory 24 consisting of a hard disk or the like are connected to the port 22. Besides, a bar code reader 40 for inputting an client code in addition to the names and prices of the chemicals is connected. Then an adjustment flip issuing means prints the name of the visited client, the names of the arranged chemicals, the usage number by chemicals and the usage money amount by chemicals. In the meantime, a person in charge inputs the money amount received from the client by an input money amount input means. A receipt issuing means prints the receipt where the received money amount is written. The sales management data is processed by CPU 20.
Weak direct currents with 2 mA are delivered 20 minutes per session (including 30s ramp-up and 30s ramp-down) during tailored upper extremity task practice. Total sessions are 20 over 10 days.
BACKGROUND: Infectious disease is an important health problem in border areas as there is a possibility that the migrants may carry the disease into the area. The purpose of this study is to evaluate the knowledge and behaviors toward human papillomavirus (HPV) and cervical cancer in the women of reproductive age in the Thailand-Myanmar border area.
METHODS: A survey study in a population of 418 women of reproductive age in Mae Hong Son Province in the Thailand-Myanmar border area. Knowledge and risk behaviors of HPV and cervical cancer were described using descriptive statistics.
RESULTS: Fifty percent of the participants had sexual debut at age less than 20 years, 27% had more than one lifetime sexual partner and only 3% had sex outside a monogamous relationship during the past 12 months. In term of knowledge, 62.5% knew about HPV. The proportion of correct answers about HPV and cervical cancer questions ranged from 14-95% and 52-94%, respectively. Among the cervical cancer screening target, 69.4% accessed the screening. The factors associated with better knowledge about HPV and cervical cancer were education level higher than high school and sexual debut.
CONCLUSION: The women of reproductive age in the Thailand-Myanmar border areas showed relatively low sexually risk behaviors for HPV infection. More than one-third of the participants did not know about HPV. The percentage of correct answer to questions about cervical cancer were low.  We encourage the Thai Ministry of Public Health to increase health promotion and health literacy on prevention of HPV and cervical cancer in the women of pre- and reproductive age in the Thailand-Myanmar border area.
Participants in this group will receive surgical planning based on physically developed and validated 3D-printed liver models from Phase One. The surgical procedures will be guided by these 3D-printed models.
Participants are randomly assigned to receive a daily dose of a sugar pill to mimic the experimental drug disulfiram for 12 weeks, while concurrently receiving methadone treatment. All participants will stop receiving all medication at week 14, at which point they will undergo a 4-week methadone detoxification period.
Potent cytochrome P450 enzyme inducers, such as carbamazepine, phenytoin, primidone, and phenobarbital, appear to increase the clearance of BANZEL (see Table 6). Given that the majority of clearance of BANZEL is via a non-CYP-dependent route, the observed decreases in blood levels seen with carbamazepine, phenytoin, phenobarbital, and primidone are unlikely to be entirely attributable to induction of a P450 enzyme. Other factors explaining this interaction are not understood. Any effects, where they occurred, were likely to be more marked in the pediatric population.

Valproate

Patients stabilized on BANZEL before being prescribed valproate should begin valproate therapy at a low dose, and titrate to a clinically effective dose. Similarly, patients on valproate should begin at a BANZEL dose lower than 10 mg/kg per day (pediatric patients) or 400 mg per day (adults) [see Dosage and Administration (2.5), Clinical Pharmacology (12.3)].
AMP-activated protein kinase (AMPK) is a typical sensor of intracellular energy metabolism. Our previous study revealed the role of activated AMPK in the suppression of osteogenic differentiation and traumatic heterotopic ossification, but the underlying mechanism remains poorly understood. The E3 ubiquitin ligase Smurf1 is a crucial regulator of osteogenic differentiation and bone formation. We report here that Smurf1 is primarily SUMOylated at a C-terminal lysine residue (K324), which enhances its activity, facilitating ALK2 proteolysis and subsequent bone morphogenetic protein (BMP) signaling pathway inhibition. Furthermore, SUMOylation of the SUMO E3 ligase PIAS3 and Smurf1 SUMOylation was suppressed during the osteogenic differentiation and traumatic heterotopic ossification. More importantly, we found that AMPK activation enhances the SUMOylation of Smurf1, which is mediated by PIAS3 and increases the association between PIAS3 and AMPK. Overall, our study revealed that Smurf1 can be SUMOylated by PIAS3, Furthermore, Smurf1 SUMOylation mediates osteogenic differentiation and traumatic heterotopic ossification through suppression of the BMP signaling pathway. This study revealed that promotion of Smurf1 SUMOylation by AMPK activation may be implicated in traumatic heterotopic ossification treatment.
* Monitor plasma factor VIII activity levels by the one-stage clotting assay to confirm the adequate factor VIII levels have been achieved and maintained, when clinically indicated. (see DOSAGE AND ADMINISTRATION).
  * Monitor for development of factor VIII inhibitors. Perform assay to determine if factor VIII inhibitor is present if expected factor VIII activity plasma levels are not attained, or if bleeding is not controlled with the expected dose of RECOMBINATE. Use Bethesda Units (BU) to titer inhibitors.
  * If the inhibitor is less than 10 BU per mL, the administration of additional RECOMBINATE concentrate may neutralize the inhibitor, and may permit an appropriate hemostatic response.
  * Adequate hemostasis may not be achieved if Inhibitor titers are above 10 BU per mL. The inhibitor titer may rise following RECOMBINATE infusion as a result of an anamnestic response to factor VIII. The treatment or prevention of bleeding in such patients requires the use of alternative therapeutic approaches and agents.
Male and female volunteer patients who were diagnosed with "Adolescent Idiopathic Scoliosis" and referred to physical therapy and met the inclusion criteria will be included in the study. Patients whose families and themselves agreed to participate voluntarily in this study will be randomly divided into three groups and included in the study. Virtual reality supported core stabilization exercises (stability enhancing exercises for the muscles around the spine), manual therapy (mobilization for the spine, mobilization and relaxation methods for the soft tissues around the spine) techniques for the second group, and both virtual reality supported core stabilization exercises and exercises for the third group were given to the third group. Manual therapy techniques will also be applied. The treatment program was planned as a total of 16 sessions, 2 days a week for 8 weeks. This study was planned as single-blind for the purpose of impartiality of the evaluation.
PURPOSE OF THE STUDY: Larger proportions of chronic obstructive pulmonary disease (COPD) patients are currently overweight or with obesity than underweight, and the combination of COPD and obesity is increasing. The purpose of this study was to investigate differences in the body composition, pulmonary function tests, exercise capacity, and health-related quality of life among normal weight, overweight, and obese patients with COPD.
STUDY DESIGN: A total of 514 patients with COPD were included in the study. According to the World Health Organization criteria for body mass index, the patients were classified as normal weight, overweight, and obese. Evaluations included fat-free mass, fat-free mass index, phase angle, pulmonary function tests, and 6-minute walk test. Dyspnea was assessed using the modified Medical Research Council dyspnea scale, and the health-related quality of life was evaluated using COPD Assessment Test and St. George's Respiratory Questionnaire. Values were compared among the three groups.
RESULTS: There were 315 male and 199 female patients, with a mean age of 66.7 ± 8.4 years. Fat-free mass, fat-free mass index, and phase angle values were significantly higher in COPD patients with obesity than in other patients (P < .001, P < .001, P < .001). Forced expiratory volume in 1 s, forced expiratory volume in 1 s/forced vital capacity, and diffusing capacity of lung for carbon monoxide value in pulmonary function tests were significantly higher in COPD patients with obesity than in other patients (P = .046, P < .001, P < .001), while the forced vital capacity values were similar in all groups. Exercise capacity (6-min walk test distance), dyspnea symptoms (modified Medical Research Council scale), and health-related quality of life (COPD Assessment Test and St. George's Respiratory Questionnaire) did not differ significantly between groups.
CONCLUSIONS: According to our study, obesity has no negative effect on pulmonary function tests, dyspnea perception, exercise capacity, and health-related quality of life.
The present disclosure relates to generating a master group node graph from a plurality of systems of record. Record objects of a system of record corresponding to a data source provider may be accessed. Each record object can have a record object type and identify a group entity. Each record object can be linked to one or more second record objects of a second record object type and identifying a respective member entity. A record object corresponding to a group entity can be identified. A connection profile between the record objects of the group entity and another group entity can be generated. An association between the group node profiles and the connection profile can be stored.
1. Method in preparation of a medicament for preventing progression of atherosclerosis in a mammal, of an aliquot of the mammal's blood which has been subjected extracorporeally to an electromagnetic emission and an oxidative environment. 2. Method according to claim 1, wherein the oxidative environment comprises applying an oxidizing agent to the aliquot. 3. Method according to claim 2, wherein the oxidizing agent contains ozone gas, and the ozone gas is introduced into the blood aliquot in an amount which does not give rise to excessive levels of mutagenicity. 4. Method according to claim 2, wherein the oxidizing agent comprises a mixture of ozone gas and medical grade oxygen, the ozone gas being contained in the mixture in a concentration of up to about 300 mug/ml. 5. Method according to claim 4, wherein the ozone has is contained in the mixture in a concentration of up to about 30 mug/ml. 6. Method according to claim 4, wherein the mixture is applied to the aliquot at a flow rate of up to about 0.33 litres/min. 7. Method according to claim 1, wherein the electromagnetic emission comprises ultraviolet light having one or more UV-C band wavelengths. 8. Use according to claim 1, wherein the aliquot is further subjected to a temperature stressor, said temperature stressor comprising a temperature above or below body temperature which does not result in substantial hemolysis of the blood is the aliquot. 9. Use according to claim 8, wherein the temperature stressor is applied so that the temperature of at least part of the aliquot is in the range of from about 5 degree C to about 55 degree C. 10. Use according to claim 9, wherein the mean temperature of the blood in the aliquot is in the range of tom about 37 degree C to about 44 degree C. 11. Use according to claim 9, wherein the mean temperature of the blood in the aliquot is in the range of from about 0 degree C to about 36.5 degree C. 12. Use according to claim 9, wherein the mean temperature of the blood in the aliquot is in the range of from about 10 degree C to about 30 degree C. 13. Use according to claim 9, wherein the mean temperature of the blood in the aliquot is in the range of from about 37 degree C to about 55 degree C. 14. Use according to claim 13, wherein the temperature is 42.5 +- 1 degree C. 15. Use according to claim 1, wherein the aliquot has a volume of up to about 400 ml. 16. Use according to claim 15, wherein the volume of the aliquot is about 10 ml. 17. Use according to claim 1, wherein the aliquot is subjected to the electromagnetic emission and the oxidative environment for a period of up to about 60 minutes. 18. Use according to claim 17, wherein the aliquot is subjected to the electromagnetic emission and the oxidative environment for a period of about 3 minutes. 19. Use according to claim 8, wherein the aliquot is simultaneously subjected to the electromagnetic emission, the oxidative environment and the temperature stressor. 20. Use according to claim 1, wherein the aliquot is simultaneously subjected to the electromagnetic emission and the oxidative environment.